Search research articles
Contact Us
Filters
Showing results (1-10 of 39) with videos related to
Page
of 4
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 19, 2003
Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment
Michael Herold, Klaus Hieke
Haematologica
|
July 2, 2002
The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use
Michael Herold, Stefano Sacchi, Klaus Hieke
Leukemia & Lymphoma
|
May 10, 2007
Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy
Stefanie Srock, Folke Schriever, Andreas Neubauer, et al.
Deutsches Arzteblatt International
|
February 26, 2021
Clinical Practice Guideline: Follicular Lymphoma—Diagnosis, Treatment, and Follow-up
Anna Zoellner, Klaus Herfarth, Michael Herold, et al.
Journal of Cancer Research and Clinical Oncology
|
March 26, 2015
Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma
Michael Herold, Christian W Scholz, Frank Rothmann, et al.
Value in Health Regional Issues
|
September 6, 2025
Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022
Christian Buske, Michael Herold, Nasim Bahar, et al.
Archives of Toxicology
|
September 29, 2022
Towards the mechanism of spermatotoxicity of p-tert-butyl-alpha-methylhydrocinnamic aldehyde: inhibition of late stage ex-vivo spermatogenesis in rat seminiferous tubule cultures by para-tert-butyl- benzoic acid
Lars Hareng, Paul Schuster, Volker Haake, et al.
Anti-Cancer Drugs
|
April 25, 2003
Rituximab therapy for indolent non-Hodgkin's lymphoma
Anton Hagenbeek, Myron S Czuczman, Michele Ghielmini, et al.
Haematologica
|
October 13, 2005
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
Manuela A Bergmann, Maria E Goebeler, Michael Herold, et al.
Anticancer Research
|
April 5, 2017
Prognostic Value of "Prepectoral Edema" in MR-mammography
Clemens G Kaiser, Michael Herold, Julia Krammer, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 39) with videos related to
Sort By:
Page
of 4
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
March 19, 2003
Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment
Michael Herold, Klaus Hieke
Haematologica
|
July 2, 2002
The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting: retrospective analysis of resource use
Michael Herold, Stefano Sacchi, Klaus Hieke
Leukemia & Lymphoma
|
May 10, 2007
Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy
Stefanie Srock, Folke Schriever, Andreas Neubauer, et al.
Deutsches Arzteblatt International
|
February 26, 2021
Clinical Practice Guideline: Follicular Lymphoma—Diagnosis, Treatment, and Follow-up
Anna Zoellner, Klaus Herfarth, Michael Herold, et al.
Journal of Cancer Research and Clinical Oncology
|
March 26, 2015
Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma
Michael Herold, Christian W Scholz, Frank Rothmann, et al.
Value in Health Regional Issues
|
September 6, 2025
Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022
Christian Buske, Michael Herold, Nasim Bahar, et al.
Archives of Toxicology
|
September 29, 2022
Towards the mechanism of spermatotoxicity of p-tert-butyl-alpha-methylhydrocinnamic aldehyde: inhibition of late stage ex-vivo spermatogenesis in rat seminiferous tubule cultures by para-tert-butyl- benzoic acid
Lars Hareng, Paul Schuster, Volker Haake, et al.
Anti-Cancer Drugs
|
April 25, 2003
Rituximab therapy for indolent non-Hodgkin's lymphoma
Anton Hagenbeek, Myron S Czuczman, Michele Ghielmini, et al.
Haematologica
|
October 13, 2005
Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group
Manuela A Bergmann, Maria E Goebeler, Michael Herold, et al.
Anticancer Research
|
April 5, 2017
Prognostic Value of "Prepectoral Edema" in MR-mammography
Clemens G Kaiser, Michael Herold, Julia Krammer, et al.
Page
of 4